TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer.

Guo-nan Zhang; Hong Liu; Jian-ming Huang; Ling Wang; Jing-sha Zhao; Chao Li; Kun Mi; Yi Zhu; Jia Cheng; Xiao Zha

首页> 外文期刊>Gynecologic Oncology: An International Journal >TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer.

【24h】

TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer.

机译：TP53 K351N突变与晚期卵巢癌患者新辅助化疗后的铂耐药相关。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

TP53 K351N mutation may be associated with induction of platinum resistance after NACT in advanced EOC.

机译：TP53 K351N突变可能与晚期EOC中NACT后诱导铂耐药有关。

著录项

来源
《Gynecologic Oncology: An International Journal》 |2014年第3期|共6页
作者
Guo-nan Zhang; Hong Liu; Jian-ming Huang; Ling Wang; Jing-sha Zhao; Chao Li; Kun Mi; Yi Zhu; Jia Cheng; Xiao Zha;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer. [J] . Guo-nan Zhang, Hong Liu, Jian-ming Huang, Gynecologic Oncology: An International Journal . 2014,第3期

机译：TP53 K351N突变与晚期卵巢癌患者新辅助化疗后的铂耐药相关。
2. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer. [J] . Matsuo K, Bond VK, Eno M International Journal of Cancer =: Journal International du Cancer . 2009,第11期

机译：在体外耐药分析中，对铂和紫杉烷化疗均具有较低的耐药性，预示着晚期上皮性卵巢癌，输卵管癌和腹膜癌患者的生存改善。
3. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma [J] . Rauh-HainJ.A., NitschmannC.C., WorleyJr.M.J., Gynecologic Oncology: An International Journal . 2013,第1期

机译：晚期上皮性卵巢癌患者新辅助化疗后的铂耐药与原发手术相比
4. CCND1 as a Predictive Biomarker of Neoadjuvant Chemotherapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma [C] . Zhien Feng, Lizhen Wang, Bingshun Wang, Academic Committee Conference of Shanghai key lab of stomatology . 2011

机译：CCND1作为局部晚期头颈部鳞状细胞癌患者新辅助化疗的预测生物标志物
5. A 3’UTR KRAS-variant as a Biomarker of Poor Outcome and Platinum Chemotherapy Resistance in Ovarian Cancer [D] . Keane, Florence Kathleen 2011

机译：3’UTR KRAS变异作为卵巢癌预后不良和铂类化疗耐药的生物标志物
6. TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma [O] . PAVLA BRACHOVA, SAMUEL R. MUETING, MATTHEW J. CARLSON, -1

机译：TP53癌变突变预测患有晚期浆液性卵巢癌的患者对铂和紫杉烷类标准化疗的耐药性
7. Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer [O] . Aurélie Pelissier, Aurélie Roulot, Béatrice Guéry, 2016

机译：血清CA125和HE4水平可作为晚期上皮性卵巢癌患者新辅助铂类化疗后最佳间隔手术和铂敏感性的预测指标

TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer.

摘要

著录项

相似文献

相关主题

期刊订阅